Rani Therapeutics (RANI) Competitors

$1.11 +0.06 (+5.71%)

Closing price 04:00 PM Eastern

Extended Trading

$1.12 +0.01 (+1.35%)

As of 06:03 PM Eastern

RANI vs. VALN, CGC, LXEO, AURA, and AVIR

Should you buy Rani Therapeutics stock or one of its competitors? MarketBeat compares Rani Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rani Therapeutics include Valneva (VALN), Canopy Growth (CGC), Lexeo Therapeutics (LXEO), Aura Biosciences (AURA), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry.

How does Rani Therapeutics compare to Valneva?

Rani Therapeutics (NASDAQ:RANI) and Valneva (NASDAQ:VALN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Rani Therapeutics has higher earnings, but lower revenue than Valneva. Valneva is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	84.23	-$29.67M	-$0.59	N/A
Valneva	$197.56M	2.59	-$130.33M	-$1.58	N/A

Rani Therapeutics currently has a consensus target price of $7.80, indicating a potential upside of 602.70%. Valneva has a consensus target price of $11.98, indicating a potential upside of 101.60%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Rani Therapeutics is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Valneva had 1 more articles in the media than Rani Therapeutics. MarketBeat recorded 6 mentions for Valneva and 5 mentions for Rani Therapeutics. Rani Therapeutics' average media sentiment score of 0.37 beat Valneva's score of -0.15 indicating that Rani Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rani Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Valneva	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rani Therapeutics has a net margin of 0.00% compared to Valneva's net margin of -67.64%. Valneva's return on equity of -76.81% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-774.04%	-106.02%
Valneva	-67.64%	-76.81%	-26.33%

30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 26.5% of Rani Therapeutics shares are owned by company insiders. Comparatively, 14.9% of Valneva shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Rani Therapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Valneva has a beta of 1.72, meaning that its stock price is 72% more volatile than the broader market.

Summary

Rani Therapeutics beats Valneva on 11 of the 16 factors compared between the two stocks.

How does Rani Therapeutics compare to Canopy Growth?

Rani Therapeutics (NASDAQ:RANI) and Canopy Growth (NASDAQ:CGC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 3.3% of Canopy Growth shares are owned by institutional investors. 26.5% of Rani Therapeutics shares are owned by insiders. Comparatively, 0.2% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Rani Therapeutics has higher earnings, but lower revenue than Canopy Growth. Rani Therapeutics is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	84.23	-$29.67M	-$0.59	N/A
Canopy Growth	$278.39M	1.55	-$429.86M	-$1.30	N/A

Rani Therapeutics currently has a consensus target price of $7.80, indicating a potential upside of 602.70%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Rani Therapeutics is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Canopy Growth	2 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Canopy Growth had 2 more articles in the media than Rani Therapeutics. MarketBeat recorded 7 mentions for Canopy Growth and 5 mentions for Rani Therapeutics. Canopy Growth's average media sentiment score of 0.95 beat Rani Therapeutics' score of 0.37 indicating that Canopy Growth is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rani Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Canopy Growth	2 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Rani Therapeutics has a net margin of 0.00% compared to Canopy Growth's net margin of -94.39%. Canopy Growth's return on equity of -46.85% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-774.04%	-106.02%
Canopy Growth	-94.39%	-46.85%	-28.95%

Rani Therapeutics has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Canopy Growth has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

Summary

Rani Therapeutics beats Canopy Growth on 9 of the 16 factors compared between the two stocks.

How does Rani Therapeutics compare to Lexeo Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are owned by institutional investors. 26.5% of Rani Therapeutics shares are owned by insiders. Comparatively, 5.3% of Lexeo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Lexeo Therapeutics had 3 more articles in the media than Rani Therapeutics. MarketBeat recorded 8 mentions for Lexeo Therapeutics and 5 mentions for Rani Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.93 beat Rani Therapeutics' score of 0.37 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rani Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lexeo Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rani Therapeutics currently has a consensus target price of $7.80, indicating a potential upside of 602.70%. Lexeo Therapeutics has a consensus target price of $18.88, indicating a potential upside of 243.18%. Given Rani Therapeutics' higher possible upside, equities research analysts clearly believe Rani Therapeutics is more favorable than Lexeo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Lexeo Therapeutics' return on equity of -47.48% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-774.04%	-106.02%
Lexeo Therapeutics	N/A	-47.48%	-41.72%

Rani Therapeutics has higher revenue and earnings than Lexeo Therapeutics. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	84.23	-$29.67M	-$0.59	N/A
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A

Rani Therapeutics has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Lexeo Therapeutics has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

Summary

Lexeo Therapeutics beats Rani Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Rani Therapeutics compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are held by institutional investors. 6.3% of Aura Biosciences shares are held by insiders. Comparatively, 26.5% of Rani Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Aura Biosciences had 12 more articles in the media than Rani Therapeutics. MarketBeat recorded 17 mentions for Aura Biosciences and 5 mentions for Rani Therapeutics. Rani Therapeutics' average media sentiment score of 0.37 beat Aura Biosciences' score of -0.41 indicating that Rani Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rani Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aura Biosciences presently has a consensus target price of $20.00, indicating a potential upside of 150.63%. Rani Therapeutics has a consensus target price of $7.80, indicating a potential upside of 602.70%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Rani Therapeutics is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Aura Biosciences' return on equity of -78.12% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
Rani Therapeutics	N/A	-774.04%	-106.02%

Rani Therapeutics has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
Rani Therapeutics	$1.63M	84.23	-$29.67M	-$0.59	N/A

Aura Biosciences has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

Summary

Rani Therapeutics beats Aura Biosciences on 10 of the 14 factors compared between the two stocks.

How does Rani Therapeutics compare to Atea Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

Rani Therapeutics has higher revenue and earnings than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$1.94	N/A
Rani Therapeutics	$1.63M	84.23	-$29.67M	-$0.59	N/A

In the previous week, Atea Pharmaceuticals had 3 more articles in the media than Rani Therapeutics. MarketBeat recorded 8 mentions for Atea Pharmaceuticals and 5 mentions for Rani Therapeutics. Atea Pharmaceuticals' average media sentiment score of 1.02 beat Rani Therapeutics' score of 0.37 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rani Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

86.7% of Atea Pharmaceuticals shares are held by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are held by institutional investors. 18.1% of Atea Pharmaceuticals shares are held by company insiders. Comparatively, 26.5% of Rani Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Atea Pharmaceuticals' return on equity of -53.22% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-53.22%	-48.44%
Rani Therapeutics	N/A	-774.04%	-106.02%

Rani Therapeutics has a consensus price target of $7.80, indicating a potential upside of 602.70%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Rani Therapeutics is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Atea Pharmaceuticals has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

Summary

Rani Therapeutics beats Atea Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get Rani Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RANI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RANI vs. The Competition

Export

Metric	Rani Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$137.30M	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-1.88	18.98	20.89	25.59
Price / Sales	84.23	176.16	522.17	62.83
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	3.26	6.74	9.86	6.70
Net Income	-$29.67M	$24.11M	$3.55B	$333.77M
7 Day Performance	19.23%	0.06%	-0.32%	0.45%
1 Month Performance	32.57%	0.81%	1.33%	4.06%
1 Year Performance	99.35%	78.08%	41.10%	36.24%

Rani Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RANI Rani Therapeutics	2.9993 of 5 stars	$1.11 +5.7%	$7.80 +602.7%	+118.0%	$137.30M	$1.63M	N/A	110
VALN Valneva	2.1683 of 5 stars	$5.17 -3.4%	$11.98 +131.6%	-8.0%	$460.67M	$197.56M	N/A	700	News Coverage Earnings Report Gap Down
CGC Canopy Growth	2.1158 of 5 stars	$1.10 -2.7%	N/A	-24.8%	$456.66M	$225.65M	N/A	3,150
LXEO Lexeo Therapeutics	2.3961 of 5 stars	$5.80 +0.5%	$18.88 +225.4%	+103.5%	$453.06M	N/A	N/A	58	Earnings Report Analyst Forecast
AURA Aura Biosciences	2.2004 of 5 stars	$8.35 +19.1%	$21.50 +157.5%	+52.5%	$450.04M	N/A	N/A	50	Earnings Report Upcoming Earnings Analyst Forecast Insider Trade Analyst Revision High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RANI) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rani Therapeutics (RANI) Competitors

RANI vs. VALN, CGC, LXEO, AURA, and AVIR

How does Rani Therapeutics compare to Valneva?

Summary

How does Rani Therapeutics compare to Canopy Growth?

Summary

How does Rani Therapeutics compare to Lexeo Therapeutics?

Summary

How does Rani Therapeutics compare to Aura Biosciences?

Summary

How does Rani Therapeutics compare to Atea Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RANI vs. The Competition

Rani Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rani Therapeutics (RANI) Competitors

RANI vs. VALN, CGC, LXEO, AURA, and AVIR

How does Rani Therapeutics compare to Valneva?

Which has higher valuation & earnings, RANI or VALN?

Do analysts rate RANI or VALN?

Does the media prefer RANI or VALN?

Is RANI or VALN more profitable?

Do insiders & institutionals believe in RANI or VALN?

Which has more volatility & risk, RANI or VALN?

Summary

How does Rani Therapeutics compare to Canopy Growth?

Do institutionals & insiders believe in RANI or CGC?

Which has better valuation and earnings, RANI or CGC?

Do analysts rate RANI or CGC?

Does the media favor RANI or CGC?

Is RANI or CGC more profitable?

Which has more risk & volatility, RANI or CGC?

Summary

How does Rani Therapeutics compare to Lexeo Therapeutics?

Do institutionals & insiders believe in RANI or LXEO?

Does the media favor RANI or LXEO?

Do analysts rate RANI or LXEO?

Is RANI or LXEO more profitable?

Which has better valuation and earnings, RANI or LXEO?

Which has more risk & volatility, RANI or LXEO?

Summary

How does Rani Therapeutics compare to Aura Biosciences?

Do insiders and institutionals believe in AURA or RANI?

Does the media refer more to AURA or RANI?

Do analysts prefer AURA or RANI?

Is AURA or RANI more profitable?

Which has stronger earnings & valuation, AURA or RANI?

Which has more risk & volatility, AURA or RANI?

Summary

How does Rani Therapeutics compare to Atea Pharmaceuticals?

Which has higher earnings and valuation, AVIR or RANI?

Does the media refer more to AVIR or RANI?

Do institutionals and insiders believe in AVIR or RANI?

Is AVIR or RANI more profitable?

Do analysts prefer AVIR or RANI?

Which has more volatility and risk, AVIR or RANI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RANI vs. The Competition

Rani Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools